Spurring Innovative Rare Disease Drug Development

February 28, 2019

Incentives provided by the Orphan Drug Act have dramatically changed the number and types of therapies that are available to patients with rare diseases.

Spotlight

Trio Medicines LTD

Trio Medicines Ltd (Trio) is a small pharmaceutical company founded in 2005, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO. Here, we focus on developing treatments for rare and unmet medical needs with the aim of improving the health and quality of life of patients around the world. Here at Trio, we are currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).

Other Infographics
news image

Pharma Technology Focus

Infographic | June 3, 2022

Pharma Technology Focus is free to read on all devices.

Read More
news image

COVID-19 Summary as of March 13, 2020

Infographic | April 6, 2020

Biomedtracker and Trialtrove have a total of 307 clinical trials for the treatment of COVID-19. 152 initiated trials for the treatment of COVID-19. 155 Trials have been announced but have not yet begun recruitment.

Read More
news image

Do patients actually watch all those pharma TV ads?

Infographic | January 13, 2020

Fewer than one in eight chronic-disease sufferers say they watch when a drug commercial comes on TV, according to one recent study of community users. And for the millennials among them, the percentage is even less so. That’s despite the $5.1 billion spent by biopharma on the medium in 2018. We take a look at these data points and many others from two recent studies on the media habits of patients and doctors.

Read More
news image

Cancer Drugs Bring in Most Pharma Revenue

Infographic | February 25, 2020

Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow even larger by 2024. This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. According to Evaluate's calculations, oncology drugs reached US$123.8 billion in sales in 2018, more than double that of the next item on the list, drugs treating diabetes with US$48.5 billion dollars in sales. By 2024, cancer drug sales are expected to almost double to US$236.6 billion dollars.

Read More
news image

Taking Pharmacy Benefits on a New Ride

Infographic | December 1, 2019

Rideshare companies like Uber and Lyft challenged the old way of doing things with a new approach. It’s not just about getting from point A to point B anymore, it’s about the experience, convenience and added value. The same applies to pass-through PBMs (pharmacy benefit managers) that are challenging the status quo to make prescriptions more affordable..

Read More
news image

Summary of Chloroquine and Hydroxychloroquine Drug-Drug Interactions

Infographic | April 7, 2020

COVID-19 is a rapidly emerging and devastating pandemic disease. Recently, chloroquine (CQ) and hydroxychloroquine (HCQ) have been suggested for possible off-label use for patients suffering from a more severe clinical course.

Read More

Spotlight

Trio Medicines LTD

Trio Medicines Ltd (Trio) is a small pharmaceutical company founded in 2005, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO. Here, we focus on developing treatments for rare and unmet medical needs with the aim of improving the health and quality of life of patients around the world. Here at Trio, we are currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).

Events